Evidence map›Paper›PMID 40273126›Full record

ArticlePloS one2025

Implementation of a high throughput automated platform for residual DNA quantitation.

Shruti B Patel, Jon Jurica, Xiaoqing Hua

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Shruti B PatelAnalytical Research and Development, Merck & Co., Inc., Rahway, New Jersey, United States of America.ORCID 0009-0008-6169-7899
Jon JuricaAnalytical Research and Development, Merck & Co., Inc., Rahway, New Jersey, United States of America.
Xiaoqing HuaAnalytical Research and Development, Merck & Co., Inc., Rahway, New Jersey, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Host cell DNA is an impurity from cell-based manufacturing processes that must be controlled and monitored to ensure drug purity and safety. Conventional methods for measurement of residual host cell DNA in therapeutic protein require numerous preparations of plates, DNA extraction from the protein samples, followed by quantification of the extracted DNA using real-time PCR (qPCR). Preparation of plates for extraction is the most laborious step, including numerous manual steps such as sample dilution, standard curve preparation, as well as reagent and sample plate preparation. Additionally, much of the work needs to be performed in a biosafety cabinet to avoid contamination. In this study, a robotic platform using a Gilson liquid handler for plate preparation for rDNA extraction is presented. This automated workflow is not only high throughput, but also shows reproducibility that is equivalent or better as compared to manual workflows. Moreover, this approach is faster than traditional extraction and reduces the risk of human error and variability and eliminates the need for manual pipetting and plate preparation. In this study, automated and manual workflows were performed side-by-side in triplicate from different purification steps from bioreactor to ultrafiltration step. Day to day variability, matrix interference, and spike recovery were assessed to demonstrate the robustness of the automated workflow.

Indexed as

DNADNA, RibosomalHigh-Throughput Screening AssaysAnimalsAutomationCHO CellsCricetulusHumansReal-Time Polymerase Chain ReactionReproducibility of ResultsRoboticsDNADNA, Ribosomal

Identifiers

PMID40273126
PMCPMC12021156

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.